Re valuations - this recent acquisition in the Cannabis space tells the story of potential. GW essentially a one product leading company.
"Jazz Pharmaceuticals has announced that it will acquire London-headquartered biopharma company GW Pharma for a total consideration of $7.2bn.GW is focused on the discovery and development of therapeutics from its proprietary cannabinoid product platform. The company’s lead product is Epidiolex (cannabidiol) oral solution, which is approved in patients aged one-year and older for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome and Tuberous Sclerosis Complex (TSC).
Fantastic news last week re Incannex 675A regulatory pathway as a multi use medication. IMO, this is as significant as the development of the cholesterol med market. And not forgetting the other significant first mover projects across CBD and Psychedelics. A US listing in this environment and the valuations attached to novel global solutions that are already taking place overseas is more than exciting! We may be very surprised what market cap is achievable.
IHL Price at posting:
26.5¢ Sentiment: Buy Disclosure: Held
